摘要
目的探讨莫西沙星治疗泌尿生殖道耐药支原体感染的疗效与安全性。方法采用支原体培养药敏检测试剂盒,筛选泌尿生殖道耐药支原体感染者58例,随机分为2组,莫西沙星组口服莫西沙星400mg治疗,每日1次,连续7d;甲砜霉素组口服甲砜霉素500mg,1日3次,7d为1个疗程。结果耐药支原体感染58例中解脲支原体(Uu)感染55例;人型支原体(Mh)感染1例;Uu+Mh混合感染2例。莫西沙星治疗后痊愈23例(79.3%),有效率93.1%,病原清除率为89.7%,甲砜霉素治疗后痊愈17例(58.6%),有效率65.5%,病原体清除率为58.6%。两组比较差异有显著性意义。结论莫西沙星是治疗泌尿生殖道耐药支原体感染高效方便、安全的药物。
Objective To evaluate the efficacy and safety of moxifloxacin in the treatment of genitourinary tract infection with drug resistance mycoplasma. Methods 58 patients infected with drug resisitance mycoplasma had been selected by susceptibility test and randomly assigned to 2 groups. Moxifloxacin group was treated with moxifloxacin tablets 400 mg, orally, once daily, for 7 days, Thiamphenicol group was treated with thiamphenicol tablets 500 mg, orally, three times daily, for 7 days. Results Among 58 patients, 55 are infected with mycoplasma urealytium（Uu）, 1 is mycoplasma hominis（Mh）, 2 are Uu and Mh combined. After moxifloxacin oral medication, 23 patients （79.3%） fully recovered. The overall effective rate is93.1%. The pathogen clearance rate is 89.7%. After thiamphenicol oral medication, 17 patients （58.6%） fully recovered. The effective rate is 65.5%. The pathogen clearance rate is 58.6%. There were significant difference between moxiloxacin and thiamphenicol groups. Conclusion Moxifloxacin is an effective, convenient, safety antibiotic for treatment of genitourinary tract infection with drug resisitance mycoplasma.
出处
《深圳中西医结合杂志》
2005年第6期328-331,共4页
Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
基金
中华医学会皮肤科研基金资助项目(编号2005020629)
关键词
莫西沙星
解脲支原体
人型支原体
药敏试验
Moxifloxacin
Mycoplasma urealytium
Mycoplasma hominis
Susceptibity test
